title: [Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature].
abstract: A 57-years old female patient with systemic sclerosis underwent a prolonged intravenous therapy during 21 consecutive days with iloprost, a stable analogue of prostacyclin. Beginning with 0.5 ng/ kg/minute the dose was increased every 2 days up to 2 ng/kg/minute. At the end of follow up, Iloprost was shown to enhance the perfusion of the finger and to improve pulmonary-function tests including the diffusion-capacity. Furthermore, the Erythrocyte Sedimentation Rate and the C-reactive protein decreased. The case report shows the necessity of a controlled study of prolonged iloprost therapy.
authors.affiliation: Medizinische Univ.-Klinik und Poliklinik III, Universitätsklinikum Charité, Berlin.
authors.forename: G
authors.initials: G
authors.lastname: Riemekasten
authors.forename: H
authors.initials: H
authors.lastname: Jepsen
authors.forename: G R
authors.initials: GR
authors.lastname: Burmester
authors.forename: F
authors.initials: F
authors.lastname: Hiepe
mesh_terms: D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage*; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D014665:Vasodilator Agents; D016285:Iloprost
vernacular_title: Iloprostgabe über 21 Tage als wirksame Therapie bei der progressiven systemischen Sklerodermie--Fallbeschreibung und Literaturübersicht.